mBio (Feb 2021)
Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses <i>In Vitro</i>
- Nathan E. Stone,
- Sierra A. Jaramillo,
- Ashley N. Jones,
- Adam J. Vazquez,
- Madison Martz,
- Lora M. Versluis,
- Marlee O. Raniere,
- Haley E. Nunnally,
- Katherine E. Zarn,
- Roxanne Nottingham,
- Ken R. Ng,
- Jason W. Sahl,
- David M. Wagner,
- Steen Knudsen,
- Erik W. Settles,
- Paul Keim,
- Christopher T. French
Affiliations
- Nathan E. Stone
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Sierra A. Jaramillo
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Ashley N. Jones
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Adam J. Vazquez
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Madison Martz
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Lora M. Versluis
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Marlee O. Raniere
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Haley E. Nunnally
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Katherine E. Zarn
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Roxanne Nottingham
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Ken R. Ng
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Jason W. Sahl
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- David M. Wagner
- ORCiD
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Steen Knudsen
- Allarity Therapeutics, Hørsholm, Denmark
- Erik W. Settles
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Paul Keim
- ORCiD
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- Christopher T. French
- Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
- DOI
- https://doi.org/10.1128/mBio.03495-20
- Journal volume & issue
-
Vol. 12,
no. 1
Abstract
New therapeutics are urgently needed in the fight against COVID-19. Repurposing drugs that are either already approved for human use or are in advanced stages of the approval process can facilitate more rapid advances toward this goal.
